中国临床药理学杂志Issue(24)：2381-2383,3.DOI:10.13699/j.cnki.1001-6821.2015.24.003
多西紫杉醇和表阿霉素新辅助化疗对三阴性乳腺癌的临床疗效评价
Clinical efficacy of neoadjuvant chemotherapy by docetaxe combined with epirubicin on triple negative breast cancer patients
摘要
Abstract
Objective To evaluate the clinical efficacy and safety of neoadjuvant chemotherapy regimen of docetaxel combined with epirubicin in the treatment of triple negative breast cancer.Methods Sixty-one triple negative breast cancer patients were divided into experiment group (n=29) and control group (n=32).Patients in experiment group were treated with docetaxel 75 mg・ m-2 intervenous drop infusion for 3 h, epirubicin 60 mg・ m-2 intervenous drop infusion, 3 weeks a cycle for 3 cycles.Patients in control group were treated with cyclophosphamide 600 mg・ m-2 , epirubicin 80 mg・ m-2 and fluorouracil 500 mg・ m-2 intervenous drop infusion, 3 weeks a cycle for 3 cycles.The clinical efficacy and adverse reaction were compared between the two groups. And the operation was taken for all the patients.Results The objective response rate were 75.9%and 40.6%in experiment and control group, which had a significant difference ( P <0.05 ) . But the pathology complete response were 2 and 0 for the experiment and control group which had no statistical difference between the two groups ( P>0.05 ) . A total of 18 cases of grade Ⅱ/Ⅲgastrointestinal reaction and 16 cases of grade Ⅱ/Ⅲ hematological toxicity were found in experiment group, and 19 cases of grade Ⅱ/Ⅲ gastrointestinal reaction, 21 cases of grade Ⅱ/Ⅲ hematological toxicity and 1 cases of grade grade of Ⅳ hematological toxicity were found in control group.The incidence rate of adverse reactions were not statistically different between the two groups (P>0.05).Conclusion The docetaxel combined with epirubicin regimen was superior to cyclophosphamide, epiru-bicin and fluorouracil regimen.关键词
三阴性乳腺癌/新辅助化疗/多西紫杉醇/表阿霉素Key words
triple negative breast cancer/neoadjuvant chemotherapy/docetaxel/epirubicin分类
医药卫生引用本文复制引用
郭伟,金功胜..多西紫杉醇和表阿霉素新辅助化疗对三阴性乳腺癌的临床疗效评价[J].中国临床药理学杂志,2015,(24):2381-2383,3.基金项目
高校自然科学基金资助项目 （）
